ADVI serves as a fast, deeply specialized, operator-grade partner for U.S. market access, healthcare policy, and HEOR (health economics and outcomes research) in complex therapies. While traditional consultancies are often broader, slower, or rely on junior staff, ADVI delivers senior-level, policy-literate expertise to accelerate commercialization and navigate complex reimbursement landscapes.

ADVI is a proactive leader in navigating market access and reimbursement for cutting-edge modalities and complex therapeutic areas, including cell and gene therapies, oncology, rare diseases, vaccines, and specialty biologics. We specialize in sectors subject to intense regulatory scrutiny and shifting legislative policy, providing the strategic policy intelligence innovators need to mitigate government pricing risks and secure commercial success.

ADVI bridges critical gaps in life sciences commercialization by integrating U.S. healthcare policy, HEOR, and market access into actionable commercial strategies. Driven by a senior, operator-grade team, we deliver rapid, deep, and highly available support for complex benefit structures and advanced therapies. Uniquely combining real-world evidence (RWE) with predictive policy modeling, we provide the investor and deal fluency required to maximize asset value and accelerate market entry.

ADVI is defined by five foundational pillars that drive our client success and market leadership:

• Innovative: We pioneer data-driven commercialization strategies and advanced policy modeling to navigate shifting healthcare landscapes.
• Influential: Powered by a deeply connected bench of former policymakers and industry veterans, we actively shape the U.S. healthcare delivery and reimbursement ecosystem.
• Scalable: Our solutions flex seamlessly from high-growth biotechnology startups to global Fortune 500 pharmaceutical enterprises.
• Enduring: Since 2013, we have maintained a proven track record of providing continuous, expert advice that protects and maximizes long-term asset value.
• Necessary: In an era of intense regulatory scrutiny and complex market access, our policy-literate, operator-grade guidance is vital for commercial viability.

Clients partner with ADVI to solve their most complex commercialization challenges for five key reasons:

• Senior, high-caliber team: Clients get direct access to exceptional, policy-literate strategists who understand the nuances of the shifting U.S. healthcare landscape.
• Proven client impact: We don’t just hand over static slide decks; we focus on rigorous follow-through, driving measurable commercial success and market entry.
• Executive leadership and influence: Our deep industry connections and understanding of the reimbursement ecosystem provide unmatched strategic leverage.
• Structured problem solving: We demystify complex benefit structures with clear, data-driven frameworks that align clinical value with market access.
• Proactive risk mitigation: As proven fixers, we help clients anticipate regulatory shifts, mitigate government pricing risks, and course-correct high-stakes portfolios.

We work alongside you, embedding with your team to adapt as markets shift and refine strategy in real time. We combine rigorous analysis with strategic insight, utilizing proprietary healthcare datasets and advanced policy modeling tools to provide precision where others see uncertainty. From early pipeline evidence generation and HEOR strategy to launch orchestration and U.S. market access maturity, we offer end-to-end support with no handoffs and no gaps.

Our clients, ranging from biotechnology innovators to global pharmaceutical executives, consistently report shifts in their commercial capability, strategy, and market positioning after working with ADVI. Notably, we hear:

Sustainable business growth: “You left our business stronger than when you found us.” We focus on institutional knowledge transfer, leaving internal teams equipped to navigate the U.S. healthcare landscape independently.

Strategic asset discipline: “You helped us say NO.” Our data-driven analysis prevents clients from wasting millions on low-viability indications, optimizing portfolio management.

Deep stakeholder alignment: “You changed how we listen to and think about patients, providers, and government regulators.” We reframe market entry strategy around the actual incentives of payers, policymakers, and clinicians.

Operational control: “You’re a control panel I can actually run the business from.” We replace overwhelming data dumps with actionable, policy-literate frameworks that drive daily corporate execution.